Fig. 5: ctDNA trajectories and clinical events. | Nature Communications

Fig. 5: ctDNA trajectories and clinical events.

From: Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay

Fig. 5

Participants’ clinical timeline and timeline of plasma collection for ctDNA analysis for A ER+ B TNBC and C HER2 + EBC. Participants who received adjuvant HER2-targeted therapy who were not classified as HER2+ at baseline had ASCO/CAP-defined HER2+ disease on surgical resection and received one year of trastuzumab as standard of care. RCB residual cancer burden, cN clinical nodal status at baseline, cT clinical tumor size at baseline.

Back to article page